Share on Facebook Share on Twitter Email
Answers.com

List of monoclonal antibodies

 
Wikipedia: List of monoclonal antibodies
Home > Library > Miscellaneous > Wikipedia

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies which are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.

Name Trade name Target Source Use
3F8 GD2 mouse neuroblastoma
Abagovomab[1] CA-125 (imitation) mouse ovarian cancer
Abciximab ReoPro ITGA2B (CD41) chimeric platelet aggregation inhibitor
Adalimumab Humira TNF-α human rheumatoid arthritis etc.
Adecatumumab[2] EpCAM (bi-specific T-cell engager) human prostate and breast cancer
Afelimomab TNF-α mouse sepsis
Afutuzumab[3] CD20 humanized lymphoma
Alacizumab pegol[4] VEGFR2 humanized cancer
ALD518[5] IL-6 humanized rheumatoid arthritis
Alemtuzumab[6] Campath, MabCampath CD52 humanized CLL, CTCL
Altumomab pentetate Hybri-ceaker CEA mouse colorectal cancer (diagnosis)
Anatumomab mafenatox glycoprotein 72 mouse non-small cell lung carcinoma
Anrukinzumab[4] (= IMA-638)[7] IL-13 humanized  ?
Apolizumab[8] HLA-DR β humanized hematological cancers
Arcitumomab CEA-Scan CEA mouse gastrointestinal cancers (diagnosis)
Aselizumab[9] L-selectin (CD62L) humanized severely injured patients
Atlizumab (= tocilizumab) Actemra, RoActemra IL-6 receptor humanized rheumatoid arthritis
Atorolimumab Rhesus factor human hemolytic disease of the newborn[citation needed]
Bapineuzumab[10] beta amyloid humanized Alzheimer's disease
Basiliximab Simulect CD25 (α chain of IL-2 receptor) chimeric prevention of organ transplant rejections
Bavituximab[1] phosphatidylserine chimeric cancer, viral infections
Bectumomab LymphoScan CD22 mouse non-Hodgkin's lymphoma (detection)
Belimumab Benlysta, LymphoStat-B BAFF human non-Hodgkin lymphoma etc.
Bertilimumab[9] CCL11 (eotaxin-1) human severe allergic disorders
Besilesomab[11] Scintimun CEA-related antigen mouse inflammatory lesions and metastases (detection)
Bevacizumab[6] Avastin VEGF-A humanized metastatic cancer
Biciromab FibriScint fibrin II, beta chain mouse thromboembolism (diagnosis)
Bivatuzumab mertansine CD44 v6 humanized squamous cell carcinoma
Blinatumomab CD19 (bi-specific T-cell engager) mouse cancer
Brentuximab vedotin[12] CD30 (TNFRSF8) chimeric hematologic cancers
Briakinumab[13] IL-12, IL-23 human psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Canakinumab[14] Ilaris IL-1β human rheumatoid arthritis
Cantuzumab mertansine C242 antigen humanized colorectal cancer etc.
Capromab pendetide Prostascint prostatic carcinoma cells mouse prostate cancer (detection)
Catumaxomab[10] Removab EpCAM, CD3 rat/mouse hybrid ovarian cancer, malignant ascites, gastric cancer
Cedelizumab CD4 humanized prevention of organ transplant rejections, treatment of autoimmune diseases
Certolizumab pegol[2] Cimzia TNF-α humanized Crohn's disease
Cetuximab Erbitux EGFR chimeric metastatic colorectal cancer and head and neck cancer
Citatuzumab bogatox[3] EpCAM humanized ovarian cancer and other solid tumors
Cixutumumab IGF-1 receptor human solid tumors
Clenoliximab CD4 chimeric rheumatoid arthritis
Clivatuzumab tetraxetan[15] MUC1 humanized pancreatic cancer
Conatumumab[3] TRAIL-R2 human cancer
Dacetuzumab[4] CD40 humanized hematologic cancers
Daclizumab Zenapax CD25 (α chain of IL-2 receptor) humanized prevention of organ transplant rejections
Denosumab[16] Prolia RANKL human osteoporosis, bone metastases etc.
Detumomab B-lymphoma cell mouse lymphoma
Dorlimomab aritox[17]  ? mouse  ?
Dorlixizumab  ? chimeric + humanized  ?
Ecromeximab[8] GD3 ganglioside chimeric malignant melanoma
Eculizumab[8] Soliris C5 humanized paroxysmal nocturnal hemoglobinuria
Edobacomab endotoxin mouse sepsis caused by Gram-negative bacteria
Edrecolomab Panorex EpCAM mouse colorectal carcinoma
Efalizumab[18] Raptiva CD11a humanized psoriasis (blocks T-cell migration)
Efungumab[1] Mycograb Hsp90 human invasive Candida infection
Elsilimomab IL-6 mouse  ?
Enlimomab pegol[19] ICAM-1 (CD54) mouse  ?
Epitumomab cituxetan[20] episialin mouse  ?
Epratuzumab CD22 humanized cancer, SLE
Erlizumab[21] ITGB2 (CD18) humanized heart attack, stroke, traumatic shock
Ertumaxomab[10] Rexomun HER2/neu, CD3 rat/mouse hybrid breast cancer etc.
Etaracizumab Abegrin integrin αvβ3 humanized melanoma, prostate cancer, ovarian cancer etc.
Exbivirumab[22] hepatitis B surface antigen human hepatitis B
Fanolesomab[23] NeutroSpec CD15 mouse appendicitis (diagnosis)
Faralimomab interferon receptor mouse  ?
Felvizumab respiratory syncytial virus humanized respiratory syncytial virus infection
Fezakinumab[24][25][26] IL-22 human rheumatoid arthritis, psoriasis
Figitumumab IGF-1 receptor human adrenocortical carcinoma, non-small cell lung carcinoma etc.
Fontolizumab[8] HuZAF IFN-γ humanized Crohn's disease etc.
Foravirumab[3] rabies virus glycoprotein human rabies (prophylaxis)
Fresolimumab[27] TGF-β human idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Galiximab CD80 chimeric B-cell lymphoma
Gantenerumab[14] beta amyloid human Alzheimer's disease
Gavilimomab[21] CD147 (basigin) mouse graft versus host disease
Gemtuzumab ozogamicin Mylotarg CD33 humanized acute myelogenous leukemia
Golimumab[22] Simponi TNF-α human rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab CD23 (IgE receptor) chimeric allergic asthma
Ibalizumab[14] CD4 humanized HIV infection
Ibritumomab tiuxetan Zevalin CD20 mouse non-Hodgkin's lymphoma
Igovomab Indimacis-125 CA-125 mouse ovarian cancer (diagnosis)
Imciromab Myoscint cardiac myosin mouse cardiac imaging
Infliximab Remicade TNF-α chimeric rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[28][29][30] CD51 human solid tumors (prostate cancer, melanoma)
Inolimomab CD25 (α chain of IL-2 receptor) mouse graft versus host disease
Inotuzumab ozogamicin[11] CD22 humanized cancer
Ipilimumab[16] CD152 human melanoma
Iratumumab[16] CD30 (TNFRSF8) human Hodgkin's lymphoma
Keliximab CD4 chimeric chronic asthma
Labetuzumab[18] CEA-Cide CEA humanized colorectal cancer
Lebrikizumab[31] IL-13 humanized asthma
Lemalesomab[21] NCA-90 (granulocyte antigen) mouse  ?
Lerdelimumab[6] TGF beta 2 human reduction of scarring after glaucoma surgery
Lexatumumab[1] TRAIL-R2 human cancer
Libivirumab[22] hepatitis B surface antigen human hepatitis B
Lintuzumab CD33 humanized cancer
Lucatumumab[4] CD40 human multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lumiliximab[2] CD23 (IgE receptor) chimeric chronic lymphocytic leukemia
Mapatumumab[10] TRAIL-R1 human cancer
Maslimomab T-cell receptor mouse  ?
Matuzumab[9] EGFR humanized colorectal, lung and stomach cancer
Mepolizumab Bosatria IL-5 humanized asthma and white blood cell diseases
Metelimumab[23] TGF beta 1 human systemic scleroderma
Milatuzumab[4] CD74 humanized multiple myeloma and other hematological malignancies
Minretumomab glycoprotein 72 mouse  ?
Mitumomab GD3 ganglioside mouse small cell lung carcinoma
Morolimumab Rhesus factor human  ?
Motavizumab[1] Numax respiratory syncytial virus humanized respiratory syncytial virus (prevention)
Muromonab-CD3 Orthoclone OKT3 CD3 mouse prevention of organ transplant rejections
MYO-029 (= stamulumab) myostatin human muscular dystrophy
Nacolomab tafenatox C242 antigen mouse colorectal cancer
Naptumomab estafenatox[32] 5T4 Fab mouse non-small cell lung carcinoma, renal cell carcinoma
Natalizumab Tysabri integrin α4 humanized multiple sclerosis, Crohn's disease
Nebacumab endotoxin human sepsis
Necitumumab[33] EGFR human non-small cell lung carcinoma
Nerelimomab TNF-α mouse  ?
Nimotuzumab[16][34] Theracim, Theraloc EGFR humanized squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nofetumomab merpentan Verluma  ? mouse cancer (diagnosis)
Ocrelizumab[16] CD20 humanized rheumatoid arthritis, lupus erythematosus etc.
Odulimomab LFA-1 mouse prevention of organ transplant rejections, immunological diseases
Ofatumumab[10] Arzerra CD20 human chronic lymphocytic leukemia etc.
Omalizumab[21] Xolair IgE humanized allergic asthma
Oportuzumab monatox[33] EpCAM humanized cancer
Oregovomab[23] OvaRex CA-125 mouse ovarian cancer
Otelixizumab[4] CD3 chimeric + humanized diabetes mellitus type 1
Pagibaximab[10] lipoteichoic acid chimeric sepsis (Staphylococcus)
Palivizumab Synagis, Abbosynagis respiratory syncytial virus humanized respiratory syncytial virus (prevention)
Panitumumab[22] Vectibix EGFR human colorectal cancer
Panobacumab[33] Pseudomonas aeruginosa human Pseudomonas aeruginosa infection
Pascolizumab[8] IL-4 humanized asthma
Pemtumomab Theragyn MUC1 mouse cancer
Pertuzumab Omnitarg HER2/neu humanized cancer
Pexelizumab[18] C5 humanized reduction of side effects of cardiac surgery
Pintumomab adenocarcinoma antigen mouse adenocarcinoma (imaging)
Priliximab CD4 chimeric Crohn's disease, multiple sclerosis
Pritumumab vimentin human brain cancer
PRO 140 CCR5 humanized HIV infection
Rafivirumab[3] rabies virus glycoprotein human rabies (prophylaxis)
Ramucirumab VEGFR2 human solid tumors
Ranibizumab[2] Lucentis VEGF-A humanized macular degeneration (wet form)
Raxibacumab[11] anthrax toxin, protective antigen human anthrax (prophylaxis and treatment)
Regavirumab cytomegalovirus glycoprotein B human cytomegalovirus infection
Reslizumab[18] IL-5 humanized inflammations of the airways, skin and gastrointestinal tract
Rilotumumab[35] HGF human solid tumors
Rituximab MabThera, Rituxan CD20 chimeric lymphomas, leukemias, some autoimmune disorders
Robatumumab IGF-1 receptor human cancer
Rontalizumab[36] IFN-α humanized systemic lupus erythematosus
Rovelizumab LeukArrest CD11, CD18 humanized haemorrhagic shock etc.
Ruplizumab[6] Antova CD154 (CD40L) humanized rheumatic diseases
Satumomab glycoprotein 72 mouse cancer (diagnosis)
Sevirumab cytomegalovirus human cytomegalovirus infection
Sibrotuzumab FAP humanized cancer
Sifalimumab[37] IFN-α humanized SLE, dermatomyositis, polymyositis
Siltuximab IL-6 chimeric  ?
Siplizumab[8] CD2 humanized psoriasis, graft-versus-host disease (prevention)
Solanezumab[33] beta amyloid humanized Alzheimer's disease
Sonepcizumab[38] sphingosine-1-phosphate humanized choroidal and retinal neovascularization
Sontuzumab[34] episialin humanized  ?
Stamulumab[16][34] myostatin human muscular dystrophy
Sulesomab LeukoScan NCA-90 (granulocyte antigen) mouse osteomyelitis (imaging)
Tacatuzumab tetraxetan AFP-Cide alpha-fetoprotein humanized cancer
Tadocizumab[34] integrin αIIbβ3 humanized percutaneous coronary intervention
Talizumab IgE humanized allergic reaction
Tanezumab[3] NGF humanized pain
Taplitumomab paptox[21] CD19 mouse cancer[citation needed]
Tefibazumab[11] Aurexis clumping factor A humanized Staphylococcus aureus infection
Telimomab aritox T 101 Fab mouse  ?
Tenatumomab[4] tenascin C mouse cancer
Teneliximab[8] CD40 chimeric  ?
Teplizumab[14] CD3 humanized diabetes mellitus type 1
TGN1412 CD28 humanized chronic lymphocytic leukemia, rheumatoid arthritis
Ticilimumab (= tremelimumab) CTLA-4 human cancer
Tigatuzumab[4] TRAIL-R2 humanized cancer
TNX-355 (= ibalizumab) CD4 humanized HIV infection
TNX-650 IL-13 humanized Hodgkin's lymphoma
TNX-901 (= talizumab) IgE humanized allergic reaction
Tocilizumab[2] (= atlizumab) Actemra, RoActemra IL-6 receptor humanized rheumatoid arthritis
Toralizumab[8] CD154 (CD40L) humanized rheumatoid arthritis, lupus nephritis etc.
Tositumomab Bexxar CD20 mouse follicular lymphoma
Trastuzumab Herceptin HER2/neu humanized breast cancer
Tremelimumab CTLA-4 human cancer
Tucotuzumab celmoleukin[16][34] EpCAM humanized cancer
Tuvirumab hepatitis B virus human chronic hepatitis B
Urtoxazumab[2] Escherichia coli humanized diarrhoea caused by E. coli
Ustekinumab[3] Stelara IL-12, IL-23 human multiple sclerosis, psoriasis, psoriatic arthritis
Vapaliximab[8] AOC3 (VAP-1) chimeric  ?
Vedolizumab integrin α4β7 humanized Crohn's disease, ulcerative colitis
Veltuzumab[4] CD20 humanized non-Hodgkin's lymphoma
Vepalimomab AOC3 (VAP-1) mouse inflammation
Visilizumab[21] Nuvion CD3 humanized Crohn's disease, ulcerative colitis
Volociximab[10] integrin α5β1 chimeric solid tumors
Votumumab HumaSPECT carcinoma-associated antigen human colorectal tumors
Zalutumumab[10] HuMax-EGFr EGFR human squamous cell carcinoma of the head and neck
Zanolimumab[2] HuMax-CD4 CD4 human rheumatoid arthritis, psoriasis, T-cell lymphoma
Ziralimumab[21] CD147 (basigin) human  ?
Zolimomab aritox CD5 mouse systemic lupus erythematosus, graft-versus-host disease

References

  1. ^ a b c d e World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information 20 (2): 48. http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf. 
  2. ^ a b c d e f g World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information 18 (1): 38. http://whqlibdoc.who.int/druginfo/18_1_2004_INN.pdf. 
  3. ^ a b c d e f g World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information 22 (2): 54. http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf. 
  4. ^ a b c d e f g h i World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information 21 (4): 52. http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf. 
  5. ^ "BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire. 
  6. ^ a b c d World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information 14 (2): 54. http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2001_INN-83.pdf. 
  7. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. http://www.wyeth.com/research/projects.  Retrieved November 19, 2008.
  8. ^ a b c d e f g h i World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information 16 (2): 47. http://whqlibdoc.who.int/16_2_2002_INN87.pdf. 
  9. ^ a b c World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information 17 (1): 37. http://whqlibdoc.who.int/17_1_2003_INN88.pdf. 
  10. ^ a b c d e f g h World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information 19 (2): 38. http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf. 
  11. ^ a b c d World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information 18 (4): 43. http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf. 
  12. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf. 
  13. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf. 
  14. ^ a b c d World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information 21 (2): 58. http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf. 
  15. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf. 
  16. ^ a b c d e f g World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information 19 (4): 50. http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf. 
  17. ^ World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information 5 (4): 5. http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf. 
  18. ^ a b c d World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information 15 (2): 54. http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf. 
  19. ^ World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information 11 (2): 90. http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf. 
  20. ^ World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information 18 (1): 93–4. http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf. 
  21. ^ a b c d e f g World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information 14 (4): 44. http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf. 
  22. ^ a b c d World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information 18 (2): 46. http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf. 
  23. ^ a b c World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information 16 (12): 44. http://whqlibdoc.who.int/16_1_2002_INN86.pdf. 
  24. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf. 
  25. ^ ClinicalTrials.gov NCT00883896 Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis
  26. ^ ClinicalTrials.gov NCT00563524 Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis
  27. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf. 
  28. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf. 
  29. ^ ClinicalTrials.gov NCT00537381 A Study of the Safety and Effectiveness of CNTO 95 in Patients Wih Metastatic Hormone Refractory Prostate Cancer
  30. ^ ClinicalTrials.gov NCT00246012 A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma
  31. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf. 
  32. ^ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information 20 (4): 34. http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf. 
  33. ^ a b c d World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information: 57. http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf. 
  34. ^ a b c d e World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information 20 (3): 227. http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf. 
  35. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf. 
  36. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf. 
  37. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf. 
  38. ^ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization". Journal of Cellular Physiology 218 (1): 192. doi:10.1002/jcp.21588. PMID 18781584.  edit
v • d • e
Human monoclonal antibodies ("-u-")
"-limu-" (immune system)
"-kinu-" (interleukin as target)
"-tumu-" (cancer immunotherapy)
"-osu-" (bone)
"-mulu-" (musculoskeletal)
"-fungu-" (fungal)
"-viru-" (viral)
"-bacu-" (bacterial)
"-ciru-" (cardiovascular)
"-neru-" (neurologic)
#WHO-EM. ‡Withdrawn from market. CLINICAL TRIALS: †Phase III. §Never to phase III
v • d • e
Mouse monoclonal antibodies ("-o-")
"-govo-" (ovarian tumor)
"-limo-" (immune system)
"-tumo-" (miscellaneous tumor)
"-leso-" (infectious lesions)
"-ciro-" (cardiovascular)
"-pro-" (prostate tumor)
"-baco-" (bacterial)
"-colo-" (colonic tumor)
§Withdrawn
v • d • e
Chimeric monoclonal antibodies ("-xi-")
"-tuxi-" (tumor/cancer immunotherapy)
"-cixi-" (cardiovascular)
"-lixi-" (immune system)
"-mexi-" (melanoma)
"-baxi-" (bacterial)
v • d • e
Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)
"-lizu-" (immune system)
"-bazu-" (bacterial)
"-cizu-" (cardiovascular)
"-nezu-"/"-neuzu-" (nervous system)
"-toxazu-" (toxin as target)
"-vizu-" (viral infections)
"-kizu-" (interleukin as target)
†Undergoing clinical trials.
v • d • e
Chimeric + humanized monoclonal antibodies ("-xizu-")
"-lixizu-" (immune system)
v • d • e
Rat-murine hybrid monoclonal antibodies ("-axo-")
"-tumaxo-" (tumor)

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)

Search unanswered questions...

Enter a question here...
Search: All sources Community Q&A Reference topics

 
 

 

Copyrights:

Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "List of monoclonal antibodies".  Read more